Earnings call transcript: Icelandic Salmon posts stronger Q3 2026 results

Icelandic Salmon’s Q3 2026 harvest rose 36.8% year over year to 5,200 tons, while EBIT swung to a EUR 1.4 million profit from a EUR 9.4 million loss; price achievement improved EUR 0.87 per kilo. Management cited improved biological performance, removal of U.S. tariffs and strong China demand, but kept 2026 harvest guidance at 20,000 tons and set 2027 guidance at 18,000 tons because of biological issues in the autumn 2025 generation. Regulatory and tax uncertainty is delaying further investment toward the company’s stated 26,000-ton potential, and net interest-bearing debt rose EUR 10.7 million to EUR 134.4 million. The article reports a flat share move, while also giving inconsistent share-price figures.

Analysis

The earnings swing is more useful as evidence of operating leverage than as proof of a durable recovery: better survival, harvest utilization and sales mix can lift per-kilo economics quickly, but those gains reverse if the affected autumn-2025 generation forces early harvest or weaker harvest quality. The key test is whether North America and Asia remain profitable destinations after freight and realized-price differentials—not simply whether Europe’s share falls. A new Keflavík–Beijing route may help logistics, but it does not establish durable pricing power; competing Icelandic and other salmon suppliers can also contest those buyers.

The balance-sheet transmission is less favorable than the headline EBIT improvement. Working-capital investment raised net debt, and quarterly cash interest paid exceeded reported EBIT; sustained biological or price setbacks would therefore constrain investment before the stated licensed-volume potential is realized. The 2027 back-loaded harvest also shifts volume and cash generation later, while higher feed costs and regulatory uncertainty limit confidence in a rapid recovery. Any upside from regulatory clarity is a 6–18 month option, not a near-term earnings driver.

Near term, Q4 biological outcomes and realized cost per kilo matter more than the quarter’s year-on-year comparison. The article gives conflicting share-price figures, so do not anchor an entry price to it. The contrarian opportunity is that the stock may be pricing persistent impairment despite improving operations; however, there is not enough evidence here to underwrite that view. Treat ISLAX as a catalyst watch, not a confirmed long.

Key Decisions for Investors

• No immediate directional position: wait for Q4 disclosure on mortality, early-harvest volume and cost per kilo. A stable or improving cost trend without further guidance cuts would strengthen the recovery thesis; materially higher costs or a harvest reduction would falsify it.
• Monitor cash conversion, not just EBIT: track working-capital use, net interest-bearing debt and liquidity alongside margins. Further debt growth despite positive operating results would weaken the equity case and increase downside sensitivity.
• Treat a long ISLAX as conditional on evidence that North American and Asian price achievement persists after freight and product mix, plus clarity on Icelandic tax and licensing rules. Verify the share-price/listing data before setting any entry or risk limit; the article’s quoted prices conflict.
• For the next 1–3 months, watch Q4 biological updates and the 2027 harvest profile; over 6–18 months, monitor legislative progress and whether deferred capex resumes. Regulatory clarity alone is not a catalyst unless it leads to funded, executable growth.